<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6FC49291-D0A1-4B11-BCE9-F042109F4CD0"><gtr:id>6FC49291-D0A1-4B11-BCE9-F042109F4CD0</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:otherNames>Carol</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200171"><gtr:id>A5E2D186-5ADD-48B8-B986-90569B1B4939</gtr:id><gtr:title>The Generation of Mouse Models to Evaluate the Role of FKRP in the Pathogenesis of Muscular Dystrophy.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200171</gtr:grantReference><gtr:abstractText>Congenital muscular dystrophy is characterised by muscle weakness either at birth or soon thereafter. There are many different forms of this disease and not all of the underlying gene defects are understood. We have recently identified a gene encoding for a protein called fukutin related protein or FKRP. Mutations in this gene appear to cause a form of congenital muscular dystrophy and also a form of limb girdle muscular dystrophy. Both are characterised by muscle degeneration and can lead to severe disability which in the early onset form is ultimately fatal. The role of the protein FKRP in the muscle fibre is unclear at the present time although its structure suggests that it may be an enzyme involved in the manufacture of a large protein called dystroglycan that is normally found at the surface of muscle fibres. Whilst we have identified the defects in the FKRP gene that cause this disease we do not understand why these lead to a muscle disease. At this time our understanding of the disease process is limited because we have to rely on muscle biopsy samples which are too small to undertake detailed protein work. We therefore need to generate a mouse with the same gene defects as we have identified in patients. These mice will allow us to understand why this disease specifically attacks muscle tissue and what factors determine its severity. The generation of these mice is essential if we are to obtain a more detailed understanding of the underlying pathology and develop pharmaceutical or gene therapeutic strategies.</gtr:abstractText><gtr:technicalSummary>The congenital muscular dystrophies (CMD) are a genetically heterogeneous group of autosomal recessive disorders, presenting in infancy with muscle weakness, contractures and dystrophic changes on skeletal muscle biopsy. We have recently identified mutations in a putative glycosyltransferase, which we have called fukutin related protein (FKRP). Mutations in the FKRP gene underlie a form of congenital muscular dystrophy (MDC1C) and limb girdle muscular dystrophy (LGMD2I). Initial indications are that mutations in this gene represent one of the most common forms of autosomal recessive muscular dystrophy. Muscle biopsies from these patients show a marked reduction in a-but not b dystroglycan together with abnormalities in laminin a2 expression. These observations suggest that perturbation of the basement membrane via the dystroglycan axis may play a central role in the pathogenesis of these diseases. The present proposal aims to make animal models of these disorders in order to determine the relationship between various FKRP mutations and the abnormal glycosylation of a-dystroglycan and other glycosylated membrane proteins. Dystroglycan is widely expressed and is known to be differentially glycosylated not only between different tissues but also within skeletal muscle where several glycoforms have been identified. Since the abnormal processing of dystroglycan also appears to be a feature of several as yet unclassified forms of muscular dystrophy, some of which are associated with severe structural brain involvement, this work will provide important insight into what appears to be a common pathogenic pathway. The generation of these animals will furthermore provide important models for future therapeutic gene replacement trials.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>662944</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Role of FKRP in dystroglycanopathies</gtr:description><gtr:id>0F83637F-CD0F-42CB-804D-80106D5EEFA6</gtr:id><gtr:impact>This project involves a collaboration between clinicians and scientitsts to evaluate stem cell function in muscle where there is a reduction in the glycosylation of Fkrp (fukutin related protein).</gtr:impact><gtr:outcomeId>E3607C39AA1-1</gtr:outcomeId><gtr:partnerContribution>Analysis of other animal models and information concerning stem cell renewal which I will apply to my own work. Intellectual input via meetings and seminars.</gtr:partnerContribution><gtr:piContribution>We generated the first animal model with a phenotype of FKRP (fukutin related protein) related forms of muscular dystrophy and phenotypically characterised this model.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>MRC funded Neuromuscular Centre</gtr:description><gtr:id>7AF9200E-097D-4DCE-801A-D22CC5140569</gtr:id><gtr:impact>Valuable information regarding patient phenotypes associated with mutations in FKRP which can then direct work in my animal model.</gtr:impact><gtr:outcomeId>tWBdqKxUhxn-1</gtr:outcomeId><gtr:partnerContribution>Seminar series, faciliated contacts within the neuromuscular field both clinical and scientific (MRC funded Centre for Neuromuscular Disorders).</gtr:partnerContribution><gtr:piContribution>Provided a resource namely an animal model.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Magazine sent to members of the Muscular Dystrophy Campaign (fund raisers and parents of affected children)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>40F60287-CB88-493D-A93C-F7BD51F8B867</gtr:id><gtr:impact>Short article in news section

Recognised as generating a useful tool for further research</gtr:impact><gtr:outcomeId>844A5552229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Limb Girdle Foundation</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Limb Girdle Muscular Dystrophy 2I Research Fund (LGMD2IRF)</gtr:fundingOrg><gtr:id>BF89594A-C992-4E85-89ED-E5DEDDDFCFA1</gtr:id><gtr:outcomeId>CsmDbgxPU4Z0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association francaise contres les myopathies</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>16E2BD7F-DDB9-4C16-9933-F62260492C02</gtr:id><gtr:outcomeId>DryTe3ZSz920</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cure CMD</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Cure CMD (Congenital Muscular Dystrophies)</gtr:fundingOrg><gtr:id>710855EC-6DBB-405C-91A0-E4EB26E77DF6</gtr:id><gtr:outcomeId>aZs3q7UcsdJ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>muscular dystrophy association</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy Association</gtr:fundingOrg><gtr:id>439D7044-DC94-41AB-A617-1737D3882434</gtr:id><gtr:outcomeId>q84nQAUSDpo0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association francaise contres les myopathies</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>1791029E-7774-4791-BF5A-AD7B4C357361</gtr:id><gtr:outcomeId>ASyLUDiMr2U0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association francais contres les myopathies</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>4CEC879C-A36C-4C52-A3B0-2A4D4CB1FAFA</gtr:id><gtr:outcomeId>62AC7E1D7F60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association francaise contres les myopathies</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>French Muscular Dystrophy Association (AFM)</gtr:fundingOrg><gtr:id>D68F390D-8A25-4618-A85F-9DCB11B53DC4</gtr:id><gtr:outcomeId>PA2zwuHitVM0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New hypomorphic mouse model for diseases related to a knock-down in function of fukutin related protein</gtr:description><gtr:id>6858C757-1FAD-49D5-8009-67DD2B5B2104</gtr:id><gtr:impact>We now know that introducing missense mutations into the mouse FKRP gene does not cause a disease phenotype as it does in human patients. However, a knock-down in FKRP levels does cause a phenotype in the mouse highlighting the differences between FKRP in the two species. This strongly suggests that further targeting of the mouse gene (as was being performed by a number of groups) will not result in a useful disease model.</gtr:impact><gtr:outcomeId>FB02D932DB9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse model for FKRP related muscular dystrophy</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Using the previous FKRP knock-down model another was generated to mimic the limb girdle phenotype</gtr:description><gtr:id>C95A02E8-F077-4C4E-8EC6-76FDF1C794E8</gtr:id><gtr:impact>We have been able for the first time to test the therapeutic potential of a compensatory enzyme in vivo. This has highlighted potential serious problems with this approach.</gtr:impact><gtr:outcomeId>rVKCPmkwh1y</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse model for LGMD</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3F93CF4B-4E00-403B-BE29-88F2DD28CEA3</gtr:id><gtr:title>Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d12a81c1a41c39038e9286100f8688e7"><gtr:id>d12a81c1a41c39038e9286100f8688e7</gtr:id><gtr:otherNames>Muntoni F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>haCQCLiiu6G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A44268D1-CC57-47A3-9587-6E147F19173C</gtr:id><gtr:title>Fukutin-related protein alters the deposition of laminin in the eye and brain.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37d446106b9e0c96a9a817a5bd2c77d7"><gtr:id>37d446106b9e0c96a9a817a5bd2c77d7</gtr:id><gtr:otherNames>Ackroyd MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>MsrF7Xs38cp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31EA7F4F-1B51-4AE4-A34E-CB33AE2EDDF2</gtr:id><gtr:title>Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c0247455a00e50e0d2f8876b067d92"><gtr:id>90c0247455a00e50e0d2f8876b067d92</gtr:id><gtr:otherNames>Godfrey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>CE9C17D1030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D752DEF-B961-45F0-A82D-A6F828E7572D</gtr:id><gtr:title>Degree of Cajal-Retzius Cell Mislocalization Correlates with the Severity of Structural Brain Defects in Mouse Models of Dystroglycanopathy.</gtr:title><gtr:parentPublicationTitle>Brain pathology (Zurich, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0813ef0c5317776a145597c2db84fc4f"><gtr:id>0813ef0c5317776a145597c2db84fc4f</gtr:id><gtr:otherNames>Booler HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1015-6305</gtr:issn><gtr:outcomeId>56dd919b91ca37.34688401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4981605-2C6E-4577-A44B-914CD4FC3EC6</gtr:id><gtr:title>Evidence of early defects in Cajal-Retzius cell localization during brain development in a mouse model of dystroglycanopathy.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0813ef0c5317776a145597c2db84fc4f"><gtr:id>0813ef0c5317776a145597c2db84fc4f</gtr:id><gtr:otherNames>Booler HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>58a1b793107041.54621004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CA95D7B-6C3B-480B-B001-BB38F1CE9CAB</gtr:id><gtr:title>Altered primary and secondary myogenesis in the myostatin-null mouse.</gtr:title><gtr:parentPublicationTitle>Rejuvenation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1d3cdc5770d45d575ad6504e903abcc"><gtr:id>f1d3cdc5770d45d575ad6504e903abcc</gtr:id><gtr:otherNames>Matsakas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1549-1684</gtr:issn><gtr:outcomeId>gkUQ37Z799L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38CAE167-377A-48A8-9A7F-B76EB4B29FC0</gtr:id><gtr:title>Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37d446106b9e0c96a9a817a5bd2c77d7"><gtr:id>37d446106b9e0c96a9a817a5bd2c77d7</gtr:id><gtr:otherNames>Ackroyd MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>877C8565590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C441B28-0803-4AB2-8D91-02DFE5EAFFF5</gtr:id><gtr:title>Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62557012b4513ba68159a8dd855f6149"><gtr:id>62557012b4513ba68159a8dd855f6149</gtr:id><gtr:otherNames>Clement EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>55D8D619044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE9570B9-25BF-4C06-B937-BFA4D268255F</gtr:id><gtr:title>Transgenic overexpression of LARGE induces a-dystroglycan hyperglycosylation in skeletal and cardiac muscle.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4947de2d8e7351716246dd2e2b612052"><gtr:id>4947de2d8e7351716246dd2e2b612052</gtr:id><gtr:otherNames>Brockington M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>fHQDkYZ25eb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCCE180E-2DD7-493D-8998-08BDCF12C8F1</gtr:id><gtr:title>220th ENMC workshop: Dystroglycan and the dystroglycanopathies Naarden, The Netherlands, 27-29 May 2016.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f5566bd69ae9c218c942f5d42996d30"><gtr:id>8f5566bd69ae9c218c942f5d42996d30</gtr:id><gtr:otherNames>Brown SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5a96dabb4ea287.18408582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8940905A-999B-4EC5-ABFB-78235FD92752</gtr:id><gtr:title>Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b543b06313b787c174fd8fee9da7b7f5"><gtr:id>b543b06313b787c174fd8fee9da7b7f5</gtr:id><gtr:otherNames>Arechavala-Gomeza V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>XbMbANusfvT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C14748E6-3FE6-409C-BCE5-672CD045055A</gtr:id><gtr:title>Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c0247455a00e50e0d2f8876b067d92"><gtr:id>90c0247455a00e50e0d2f8876b067d92</gtr:id><gtr:otherNames>Godfrey C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>6FCF1AF9254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B51E440-1FD0-4601-906F-02E6561DFD51</gtr:id><gtr:title>Prenatal muscle development in a mouse model for the secondary dystroglycanopathies.</gtr:title><gtr:parentPublicationTitle>Skeletal muscle</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/777f83df34e1859c83cdf51578caf9d5"><gtr:id>777f83df34e1859c83cdf51578caf9d5</gtr:id><gtr:otherNames>Kim J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-5040</gtr:issn><gtr:outcomeId>56dd91f9559af4.51194023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DFC72B0-95F2-4B76-A2F7-6334D5293254</gtr:id><gtr:title>Flow cytometry analysis: a quantitative method for collagen VI deficiency screening.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/777f83df34e1859c83cdf51578caf9d5"><gtr:id>777f83df34e1859c83cdf51578caf9d5</gtr:id><gtr:otherNames>Kim J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>eMzkPxQ3Prw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7983C078-5135-456F-8791-2EBB4B0C7CD0</gtr:id><gtr:title>A comparative study of alpha-dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation of alpha-dystroglycan does not consistently correlate with clinical severity.</gtr:title><gtr:parentPublicationTitle>Brain pathology (Zurich, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5703e5b71ddfea213fe1caef5141549"><gtr:id>a5703e5b71ddfea213fe1caef5141549</gtr:id><gtr:otherNames>Jimenez-Mallebrera C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1015-6305</gtr:issn><gtr:outcomeId>9036C1A5F00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17FD8475-222B-4E93-A480-3E6ADFD9A448</gtr:id><gtr:title>Defects in glycosylation impair satellite stem cell function and niche composition in the muscles of the dystrophic Large(myd) mouse.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b90fcb86f8ff0ef88ec4421190f7ff22"><gtr:id>b90fcb86f8ff0ef88ec4421190f7ff22</gtr:id><gtr:otherNames>Ross J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>pm_14992_22_22887880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2349376E-0748-40D5-8763-2C064CB2E561</gtr:id><gtr:title>Third International Workshop for Glycosylation Defects in Muscular Dystrophies, 18-19 April 2013, Charlotte, USA.</gtr:title><gtr:parentPublicationTitle>Brain pathology (Zurich, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08bda53eb27a7b9e5960abe919e09016"><gtr:id>08bda53eb27a7b9e5960abe919e09016</gtr:id><gtr:otherNames>Blaeser A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1015-6305</gtr:issn><gtr:outcomeId>56dd919bb649f6.80141828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F445DB57-BA0F-4F05-A1C0-78BD24217141</gtr:id><gtr:title>Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e3a3043c15917b0e2b85faeda6cd6e"><gtr:id>66e3a3043c15917b0e2b85faeda6cd6e</gtr:id><gtr:otherNames>Neri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>DGSKTL5c1CN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A4D4ABF-8FE6-40BE-A75A-1F578D11088D</gtr:id><gtr:title>Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4fce7b8647f33002b39164a8fe9997"><gtr:id>1a4fce7b8647f33002b39164a8fe9997</gtr:id><gtr:otherNames>Hildyard JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58a1b7cba922d4.96019405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA922004-014B-4DFD-A467-E446B432D953</gtr:id><gtr:title>The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e22a3ff7b2f2f08f0e1cfac1e9d3527"><gtr:id>4e22a3ff7b2f2f08f0e1cfac1e9d3527</gtr:id><gtr:otherNames>Whitmore C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_14992_hmg_ddt577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F7DE2FB-ADB9-408F-ABC5-A7A84C023FEC</gtr:id><gtr:title>The dystrophin-glycoprotein complex in brain development and disease.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9917cfb1a0ae07b2cb80a76a82779fe5"><gtr:id>9917cfb1a0ae07b2cb80a76a82779fe5</gtr:id><gtr:otherNames>Waite A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>pm_14992_22_22626542</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200171</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>